Highlights ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Market Closed - Toronto S.E. Other stock markets 19:30:43 27/06/2024 BST			5-day change	1st Jan Change
1.02 ^CAD	+8.51%		+0.99%	+13.33%

06-04	ZYUS Life Sciences Corp. Brief: Says Cannabis Drug License Enables It to Expand its Clinical Research Activities by Manufacturing Drugs Containing Cannabis in Canada	MT
06-04	ZYUS Life Sciences Corp. Brief: Lost 4.6% on Monday, But Today Said It Received Cannabis Drug License from Health Canada	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ZYUS Life Sciences Corp. Brief: Says Cannabis Drug License Enables It to Expand its Clinical Research Activities by Manufacturing Drugs Containing Cannabis in Canada	06-04	MT
ZYUS Life Sciences Corp. Brief: Lost 4.6% on Monday, But Today Said It Received Cannabis Drug License from Health Canada	06-04	MT
ZYUS Life Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	05-07	CI
ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate	04-23	MT
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	03-05	MT
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	02-20	MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	02-20	MT
ZYUS Life Sciences Corp. Announces Phase 2 Trial Evaluating Trichomylin Softgel Capsules for Advanced Cancer Pain Care	12-05	MT
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management	12-05	CI
ZYUS Life Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-30	CI
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels	11-21	MT
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels	11-21	CI
ZYUS Life Sciences Inc. completed the acquisition of Phoenix Canada Oil Company Limited in a reverse merger transaction.	08/06/23	CI
Phoenix Canada Oil Completes C$20.13-Milion Subscription Receipt Placement Ahead of Reverse Takeover	06/06/23	MT
Phoenix Canada Oil Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23/04/23	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/11/22	CI
Phoenix Canada Oil Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	18/08/22	CI
Phoenix Canada, ZYUS Life Sciences Sign Letter of Intent for Reverse Takeover Transaction	30/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Highlights

Filters